Multiple oncogenic pathways, such as mTORC1 signaling, E2F targets, KRAS signaling, and the estrogen response have been found up-regulated in breast cancer cells with acquired resistance to CYH3329. This evidence concerns the gene KRAS and breast carcinoma.